Technology
Health
Pharmaceutical
Kiniksa Pharmaceuticals
$15.009876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$15.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.31 (-2.02%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell KNSA and other stocks, options, ETFs, and crypto commission-free!
About
Kiniksa Pharmaceuticals, Ltd. Class A Common Stock, also called Kiniksa Pharmaceuticals, is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Read More Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
Employees
111
Headquarters
Hamilton, Hamilton
Founded
2015
Market Cap
820.39M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
126.02K
High Today
$15.45
Low Today
$14.81
Open Price
$15.11
Volume
13.80K
52 Week High
$32.88
52 Week Low
$13.04
Collections
Technology
Health
Pharmaceutical
Biopharmaceutical
Medical
2018 IPO
North America (Non-US/Canada)
North America
News
Yahoo FinanceApr 29
Is Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent?
Yahoo FinanceApr 23
Long-Term "GameChangers" in Biotech
When I’m hunting for unicorns, I start with biotech. They won’t all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers. Start at the earliest stage of development with Kaleido BioSciences (KLDO), which just went public on February 28. It is not much to look at today. The company has a dream of harnessing the body’s internal microorganisms to clean harmf...
Price Paid on Robinhood
16% Lower
Right Now
52 Week Low
$13.04
Average Price Paid
$17.75
52 Week High
$32.88
Earnings
-$1.27
-$0.99
-$0.72
-$0.44
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 5, Pre-Market